able and willing to travel abroad to a proton facility. Commonly accepted indications for referral include chordoma and chondrosarcoma, intraocular melanoma, and solid tumours in children and adolescents who have the greatest risk for long-term sequelae.
INTRODUCTION
In proton-beam therapy (pbt), high-energy protons enter the body, depositing less radiation dose at the body surface and most at the end of their range, deep in tissue (called the Bragg peak). The result is a minimal dose deep to the target, sharply contrasting with the exponential attenuation of dose along the beam path of photons (X-rays). The result is that pbt can spare radiation dose to healthy uninvolved tissues outside the target, potentially reducing the risk of radiation injury 1 .
By December 2013, 111,088 patients worldwide had been treated with pbt 2 . Historically, the high capital cost of proton facilities equipped with rotational gantries (exceeding US$160 million) 3 has limited the number of facilities in operation; however, that number is now increasing rapidly (see Table i ). In the 10 years up to 2014, the number of facilities in the United States alone grew to thirteen from two 3 . Compact single-room cyclotron centres have drastically reduced the capital cost (estimated at less than US$50 million) and account for 10 of the 22 facilities under construction worldwide 2 . In Canada, the triumf Proton Treatment Facility in Vancouver, British
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Methods
The medline, embase, PubMed, and Cochrane databases were systematically searched for studies published between January 1990 and May 2014 that evaluated clinical outcomes after pbt. A draft report developed through a review of evidence was externally reviewed and then approved by the Alberta Health Services Cancer Care Proton Therapy Guidelines steering committee.
Results
Proton therapy is often used to treat tumours close to radiosensitive tissues and to treat children at risk therapy (rt). In uncontrolled and retrospective studies, local control rates with pbt appear similar to, or in some cases higher than, photon rt. Randomized trials comparing equivalent doses of pbt and photon rt are not available.
Summary
Referral for pbt is recommended for patients who are being treated with curative intent and with an expectation for long-term survival, and who are Curr Oncol, Vol. 21, pp. 251-262; doi: http://dx.doi.org/10.3747/co. 21.2207 additional citations.
A search for ongoing trials at http://clinicaltrials. gov/ involving pbt, including 20 randomized controlled trials (rcts), of which only 6 are comparing pbt with photon radiation therapy (rt).
Recommendation Development
The present report was produced by the Alberta Health Services (ahs) Cancer Care Proton Therapy Guidelines working group through review and interpretation of evidence. The working group was tasked with drafting guidelines and clinical pathways for the care of patients who could potentially be candidates for pbt. The draft report was distributed by electronic survey to 17 Alberta physicians (59% response rate) from across tumour groups for external review. Feedback was incorporated into the draft, which was then approved by the steering committee and posted on the external ahs Web site in March 2013 (updated in June 2014). 1  Austria  1  Italy  1  Poland  1  Saudi Arabia  1  Sweden  1  Taiwan  1  Netherlands  4  England  2  TOTAL  29  22  9 a First patient to be treated during or before 2016.
figure 1 Literature search, draft preparation, and validation process.
The report was developed as part of the mandate of the ahs Proton Therapy Referral Committee to provide advice to the Out-of-Country Health Services Committee that considers funding for patients referred for medical care to facilities outside Canada.
RESULTS
Pediatrics
Childhood cancer survivors who undergo rt are at high risk of deleterious effects on growth and development and of tissue late effects, including secondary malignancies 5 . Models strongly suggest a lower risk of secondary malignancies in children treated with pbt because of improved dose distribution and a lower volume of normal tissue exposed to radiation 6, 7 . Preliminary data from a review of 86 children with retinoblastoma demonstrated a lower 10-year cumulative incidence of rt malignancies with pbt than with photon rt (0% vs. 14%, p = 0.015) 8 . A review of 558 patients treated at the (then) Harvard Cyclotron Laboratory, matched to 558 patients from the Surveillance, Epidemiology, and End Results database who received photon rt, demonstrated fewer subsequent cancer events after pbt (4.2% vs. 7.5%; adjusted hazard ratio: 0.52; p = 0.009) 9 . However, limitations in epidemiologic data prevent conclusions being drawn 10 .
The rational for using pbt for central nervous system (cns) lesions is compelling. Compared with photon intensity-modulated rt (imrt), pbt can achieve substantial sparing of normal tissue during craniospinal irradiation in medulloblastoma (including the cochlea and heart 11 ) and during boost therapy (hippocampus 12 and subventricular zone 13 ). In Monte Carlo simulations comparing pbt with photon rt for -ciencies, cardiac disease, and secondary malignancies in medulloblastoma survivors, pbt was found to be cost-effective and to be associated with greater quality-adjusted life years 14 . In 96% of simulations, pbt outperformed photon rt -lectual and academic decline that follow cranial rt 15 were not modelled because of a lack of cost data for productivity loss secondary to cognitive decline. Despite concerns that linear energy transfer variations in proton beams can alter patterns of failure, a review of 109 children with medulloblastoma treated with pbt suggested that the patterns of failure were similar to those with photon rt 16 .
For craniopharyngiomas, planning studies show that, compared with imrt, pbt delivers a lower integral dose to the hippocampus, dentate gyrus, and subventricular zone 17 and a lower dose to the optic chiasm, cochlea, brain, and scanned body 18 . In 5 children and 10 adults treated with combined proton-photon rt, Fitzek et al. 19 reported actuarial 5-and 10-year local control rates of 93% and 85% respectively.
Young age, proximity to critical structures, and expectation for a high tumour control rate make pbt an ideal modality for children with ependymoma 20 . A review of 70 children with intracranial ependymoma treated with pbt reported high rates of 3-year local control and overall survival (83% and 95% respectively) at a median follow-up of 46 months 20 . Few children treated with pbt developed growth hormone n = 2), central hypothyroidism (n = 1), or hearing loss (n = 2). Amsbaugh et al. 21 reported local control and overall survival rates of 100% at a mean follow-up of 26 months in 8 children with spinal ependymoma treated with pbt. No patients experienced grade 3 or greater adverse events.
Studies of tumours outside the cns-including skull base chordoma and chondrosarcoma 22, 23 , uveal melanoma 23, 24 , germ-cell tumours 25 , high-risk neuroblastoma 26, 27 , parameningeal rhabdomyosarcoma 28 , bladder and prostate rhabdomyosarcoma 29 , other soft tissue sarcomas 30 , Ewing sarcoma 31 , and mediastinal Hodgkin lymphoma 32 -uniformly showed that pbt is well tolerated, with local control rates similar to or higher than those achieved with photon rt. Although planning studies and early clinical results are promising, long-term data supporting a clear advantage of pbt over photon rt are not yet available. Increased enrollment into clinical trials, including multicentre and registry trials with appropriate statistical designs and long-term follow-up, is needed 33 .
Chordoma and Chondrosarcoma
Chordoma and chondrosarcoma often occur in close proximity to critical neural tissues such as the optic pathway, brainstem, or sacral plexus, posing challenges in the delivery of curative doses of rt. Historical series of photon rt demonstrated 5-year local control rates in the 20% range 34, 35 , which improved in small series of stereotactic 36 and image-guided rt 37 (published only in abstract form) to 50% and 77% respectively for skull base chordoma and to 100% and 93% respectively for skull base chondrosarcomas. A review of 621 patients treated with combined proton-photon rt at the Harvard Cyclotron Laboratory reported 5-year local relapse-free and overall survival rates of 73% and 80% respectively for skull base chordoma and 98% and 91% respectively for skull base chondrosarcomas 38 . Similar results from the Paul Scherrer Institute were reported with spot-scanned intensity-modulated proton therapy, including 94% freedom from grade 3 or 4 toxicity at 5 years 39 . Full-dose re-irradiation for recurrent or progressive chordoma, with or without salvage surgery, demonstrated encouraging 2-year rates of local control (85%) and overall survival (80%), with late grade 3 or 4 toxicity occurring in 3 of 16 cases 40 .
Delaney et al. reported long-term results of a phase ii study of combined proton-photon rt for spinal chordoma, chondrosarcoma, and other sarcomas. The 8-year actuarial local control was 85% for primary tumours 41 . Randomized data comparing proton with photon rt are not available. Differences in outcome for those rt modalities are confounded by extent of resection, dose escalation, and patient selection biases.
Intraocular Melanoma
Management of intraocular melanoma aims to preserve the eye and functional vision while achieving a high rate of tumour control. Protons are useful in treating larger tumours or tumours close to the fovea or optic disc that are not suitable for plaque brachytherapy. Local control and eye preservation rates exceed 90% at 5 years [42] [43] [44] [45] [46] . In 59 patients treated with pbt at triumf in Vancouver, the 5-year actuarial local control rate was 91% (97% in patients treated with 60 GyE), with an overall eye conservation rate of 80% 46 . The 5-year actuarial rate of neovascular glaucoma was 31% at a median follow-up of 63 months. Radiation retinopathy (74%) and optic neuropathy results compare favourably with results from series using stereotactic photon rt, which spares the patient from surgical insertion of localization clips 47, 48 . However, in the Canadian series, Krema et al. 47 reported higher actuarial rates of neovascular glaucoma (42% after a short median follow-up of 37 months) than were reported with proton rt 46 .
A single-centre review of 2069 patients treated with pbt demonstrated a 15-year actuarial local control rate of 95% 49 . The cumulative rate of enucleation was 16%, most frequently because of neovascular glaucoma, blindness with ocular discomfort, or local recurrence. In an effort to reduce toxicity, Gragoudas et al. 50 randomized 188 patients to standard or reduced-dose pbt with maintenance of local control and metastatic death rates, in those receiving the lower dose. In a review of 597 patients, Wilson and Hungerford 51 reported similar local control rates with pbt and 125 I plaque brachytherapy. A review of 73 patients with recurrence after pbt suggested that, compared with enucleation, re-irradiation with pbt does not compromise overall survival 52 .
Central Nervous System
The dosimetric advantages of pbt compared with photon rt include the former's ability to deliver high doses with steeper gradients to nearby critical structures. Whether those advantages result in a reduction in late effects such as neurocognitive function, vascular events, and second malignancies requires evaluation. For high-grade glioma, pbt has resulted in survival times typical for highly selected patients 53 , but pbt is likely more useful in the treatment of benign tumours such as arteriovenous malformations (avms), meningiomas, acoustic neuromas, and pituitary adenomas, effects, including secondary malignancies.
Among 248 patients with 254 cerebral avms (23% in deep locations) treated with single-fraction proton stereotactic radiosurgery (psrs), the median time to total obliteration was 31 months, and the 5-and 10-year cumulative incidences of total obliteration were 70% and 91% respectively, comparing favourably with obliteration rates reported using photon radiosurgery, including Gamma Knife (Elekta, Stockholm, Sweden) 54 . In 59 patients with high-risk cerebral avms treated with two-fraction psrs because of large size or eloquent brain location, median time to total obliteration was long at 62 months, with a low 5-year actuarial total obliteration rate of 33% 55 . Median time to obliteration was similar (49 months) in 44 children with high-risk cerebral avms treated with psrs 56 . Those data suggest that avms can be safely treated with psrs; however, no randomized comparisons between proton and photon rt have been published.
Studies of benign meningiomas treated with pbt show local control rates that are comparable to those achieved with photon rt 57-60 . In an older study, the use of pbt without modern spot-scanning and imageguidance appeared to be associated with worse morbidity than was seen with contemporaneous photon rt 60 . For acoustic neuromas, 100% local control at a mean follow-up of 34 months was observed in 30 patients with poor hearing treated with pbt 61 . Among 88 patients treated with single-fraction psrs, the 5-year actuarial local control was 94% 62 . The 5-year actuarial rates for preservation of normal facial and trigeminal nerve function were 91% and 89% respectively and appeared to be higher than those seen with low-dose photon radiosurgery 63 , but the differences could have been a result of patient selection.
Proton craniospinal irradiation has been proposed to spare dose to vertebral bodies and to reduce acute gastrointestinal and hematologic toxicity in adults 64 . In 40 adults with medulloblastoma, less nausea and vomiting, weight loss, and hematologic toxicity was associated with proton craniospinal irradiation than with photon rt, with 2-year overall survival being similar 65 .
Head and Neck
Multiple in silico studies have demonstrated dosimetric advantages for pbt in head-and-neck cancers, but clinical data are limited 1 . Data for sinonasal tumours are particularly encouraging [66] [67] [68] [69] . Resto et al. 66 reviewed 102 patients with locally advanced sinonasal tumours of varying histologies treated with pbt alone or combined with photons. The 5-year rates of local control and overall survival were, respectively, 95% and 90% with complete resection, 82% and 53% with partial resection, and 87% and 49% with biopsy alone. Truong et al. 69 70 . In other head-and-neck cancers, limited data indicate that toxicity tends to be lower with pbt and that rates of local control and survival are similar to those achieved with photon rt 70 .
Prostate
More
rt. An increase in local control with higher dose was noted for subjects with high-grade disease. In the prog-9509 study, 393 patients with clinically localized prostate cancer received pbt boosts of rt (50.4 Gy) 73 . Higher rt reduced the 10-year biochemical failure rate (7.1% vs. 28.2%, p < 0.0001) without increasing grade 3 or greater late urinary or rectal morbidity. A case-match analysis of the 196 men on the high-dose arm of that trial and 203 similar men treated with brachytherapy revealed similar 8-year biochemical failure rates 74 . Kim et al. 75 randomized 88 T1-3 prostate cancer patients to 5 hypofractionated arms that showed similar biochemical control rates and low rates of grade 3 or greater toxicity (2%); however, a control arm of standard fractionation was not included.
The University of Florida reported 5-year patientreported outcomes from three prospective trials of image-guided proton-only therapy 76 . Prospectively were similar in 1243 men after pbt and 204 men after imrt 77 . Gray et al. 78 reported that pbt, conformal photon rt, and imrt all result in similar clinically meaningful reductions in bowel (but not urinary) quality-of-life scores at 24 months.
Retrospective data from the Surveillance, Epidemiology, and End Results database comparing pbt with imrt are controversial 79, 80 . A review of 27, 647 in toxicity at 12 months after treatment and substantially higher cost for pbt compared with imrt 71 .
of using pbt is lower mean integral dose, potentially reducing the risk of secondary malignancies 81 , but clinical data are lacking. Currently, pbt appears to imrt for the management of patients with prostate cancer.
Other Sites
Other sites-including breast and lung cancers, gastrointestinal tract malignancies, and lymphoma-are reviewed in the full report available on the external Web site http://www.albertahealthservices.ca/hp/ if-hp-cancer-guide-rt002-proton-beam-rt.pdf. For those disease sites, pbt demonstrates no clear advantages over photon rt.
DISCUSSION
Adoption of new technologies in situations of un- [82] [83] [84] . Many innovations, including cobalt-60 units, linear accelerators, electron beams, imrt, and image-guided rt, have entered into clinical practice without phase iii rct evidence 82 . The guiding principle for those advances was to deliver doses "as low as reasonably achievable" (alara principle). The current situation with respect to pbt is similar, with numerous dosimetric studies demonstrating potential advantages with pbt 85 . It has been argued that randomization between proton and photon rt would be unethical because normal tissues would be exposed to extra dose without any anticipated gain in the tumour control achieved with photons 82 . Fully informed patients aware that the risk of radiation injury increases with dose and volume irradiated might, appropriately, be unwilling to enrol in rcts. Goitein and Cox 83 have questioned whether equipoise, a state of genuine uncertainty about the superiority between two treatments 86 , can be met in this situation, but others disagree 84 . Uncertainties about the range of protons in tissue (arising from patient set-up and motion, beam delivery, and dose calculation), especially in the spot-scanning of moving targets, could limit the pbt 87 . Despite the controversies, efforts to generate high-level evidence are under way, including six rcts comparing proton and photon rt. The multicentre partiqol rct in patients with low-risk and low-tointermediate-risk prostate cancer is comparing bowel quality-of-life as the primary endpoint (http:// clinicaltrials.gov/show/NCT01617161). The Radiation Therapy Oncology Group is comparing overall survival in patients with inoperable non-small-cell lung cancer (http://clinicaltrials.gov/show/NCT01993810). These studies include cost effectiveness and qualityof-life as secondary endpoints. Enrollment at the MD Anderson Cancer Centre into four rcts of intensity-modulated proton therapy compared with imrt for glioblastoma (http://clinicaltrials.gov/show/ NCT01854554), head-and-neck cancer (http://clinical trials.gov/show/NCT01893307), and esophageal cancer (http://clinicaltrials.gov/show/NCT01512589), and stereotactic body proton versus photon rt for non-small-cell lung cancer (http://clinicaltrials.gov/ show/NCT01511081) include late effects as a primary endpoint. Large registry studies collecting qualityof-life data in pediatric (http://clinicaltrials.gov/show/ NCT01115777) and adult patients (http://clinicaltrials. gov/show/NCT01255748) have proceeded. In silico trials, such as those from the rococo consortium 88 , could help to guide clinical trial development.
The lack of rcts comparing proton with photon rt required our working group, like other authors 1,89-97 , to make recommendations based on prospective coet al. 1 suggested that patients with the highest priority for chargedparticle therapy include those with chordomas or chondrosarcomas of the skull base, large uveal and mucosal melanomas, large unresectable sarcomas, renal cell carcinoma, pancreatic and liver cancers, and most pediatric patients. In 2012, the emerging technology committee of the American Society for pbt for large ocular melanomas and chordomas and the pediatric patients 89 . That report suggested the superiority of proton over photon rt for pediatric cns -pbt outside of clinical trials in head-and-neck, lung, gastrointestinal, and non-cns pediatric cancers. Three systematic reviews published in 2007 reported pbt for most disease sites [90] [91] [92] ; however, one concluded that the pbt in chordomas and large ocular tumours, while not reviewing pediatric indications 92 .
In June 2014, the American Society for Radiation Oncology released a model policy to address coverage for pbt 93 . Their policy considers pbt reasonsparing of surrounding normal tissue that cannot be adequately achieved using photon rt-for example, when the target volume is close to one or more critical structures and a steep dose gradient outside the target must be achieved, when a decrease in dose inhomogeneity is needed to avoid an excessive dose hotspot, when a photon technique would increase the risk of clinically meaningful normal-tissue toxicity, or when the same or an immediately adjacent area has previously been irradiated. England, Denmark, and the Netherlands have released national guidelines for pbt referral (Table ii) .
Factors other than diagnosis should be taken into account when deciding whether pbt confers a rt. The working group recommends that, to ensure that rethat could be reduced with pbt, the treatment intent should be curative and the patient's expected survival should be 5 years or more. In Alberta, criteria disease or cases involving re-irradiation (which are excluded in the English guidelines 94 ). Not all patients will be able and willing to relocate to a foreign city, often for 6-8 weeks, for pbt treatment planning and -cial consequences patients endure while away from home cannot be overstated 85 . Fully informed patients should be told of the lack of high-level evidence supporting pbt. Patients or parents of pediatric patients who cannot travel for pbt for whatever reason could potentially be left with lifelong guilt that they did not undergo "optimal" treatment 85 . The working group recommends that every referral be discussed by a multidisciplinary team to provide transparency and accountability in the selection process. In Alberta, that team requests generation of proton and photon rt treatment plans for an assessment of the magnitude pbt in cases in which the pbt is unclear.
in most facilities currently in operation 98, 99 . Most published clinical studies are of patients treated with -ing layers and overall dose delivery are advantages collimators (apertures) to laterally shape the beam 100 . In uniform scanning, a proton pencil beam is magnetically scanned in lateral 101, 102 . Because no scattering material is in the beam path, the maximum range of such beams is slightly higher, but as needed for uniform scanning 100 . In spot scanning, a proton pencil beam is scanned over the target without the need for an aperture or compensator 103 . This technology, available in a limited number of facilities, allows for the delivery of intensity-modulated proton therapy. Relative to imrt, neutron contamination from passively-scattered proton beams potentially increases the risk of secondary malignancies 5 , but spot-scanning drastically reduces neutron production 104 . An evaluation of whether young children should be referred only to spot-scanning facilities is required.
The economics of referral will become increasingly important as patient volumes increase. In Alberta, the number of referrals more than doubled in the year after recommendations were posted on the external Web site ( Table iii) . The working group recommends that patients with intraocular melanomas be sent to the triumf facility in Vancouver to minimize out-of-country costs. Cost savings for other diagnoses could potentially be achieved by negotiation of provincial contracts with one or more preferred pbt providers. Referral to a single facility could also potentially promote communication and research collaboration 105 
SUMMARY
Evidence from a literature review, consensus of expert opinion, feedback obtained through a review committee form the basis of these recommendations, which were completed in March 2013 and updated in June 2014.
Target Population
These recommendations apply to pediatric and adult patients being considered for treatment with rt. (Figure 2 ). 7. Patients with intraocular melanomas should be referred to the triumf Proton Treatment Facility in Vancouver. Other patients will require referral to a proton facility outside Canada. A current list of facilities in operation is available on the Particle Therapy Co-Operative Group Web site 2 .
Recommendations
Qualifying Statement
Funding for referral for pbt is generally considered on a case-by-case basis by the Ministry of Health in each province. In Alberta, the Out-of-Country Health Services Committee, a regulated committee operating at arm's length from the Ministry of Health and Alberta Health Services, reviews applications for hospital and physician services that are not available in Canada. Applications for pbt referral require documentation of case review at the ahs Proton Therapy Referral Committee multidisciplinary rounds, where discussion follows the recommendations reported here.
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